Trial
NCT02824575
Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Montefiore Medical Center
Collaborators
Deciphera Pharmaceuticals, LLC; Albert Einstein College of Medicine
Condition
Breast Cancer
Intervention
Rebastinib
Why stopped
Unfortunately, Deciphera management decided to not move forward with the rebastinib program and are terminating early.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-04-04